Turkey: Brace for Impact! The European Union Files A Complaint Against Turkey's Pharmaceutical Regulations Before the World Trade Organization

Last Updated: 11 June 2019
Article by Sahin Ardiyok and Armanç Canbeyli

On 2 April 2019, the European Union ("EU") requested initiated a formal dispute before the World Trade Organization ("WTO") against Turkey's program to localize the production of the pharmaceutical products in Turkey. The consultation request focuses on the measures adopted by the Turkish government in 2016 to promote the local production of pharmaceutical products, which are otherwise imported into the country. The EU argues that the measures adopted Turkey are in contradiction with its obligations under the General Agreement on Tariffs and Trade ("GATT"), the Agreement on Trade Related Investment Measures ("TRIMs"), the Agreement on Trade – Related Aspects of Intellectual Property Rights ("TRIPS") and the Agreement on Subsidies and Countervailing Measures ("SCM"). Subject to the outcome of the procedural consultations between the EU and Turkey under the rules-based system of the WTO, the disputes seems to be evolving into a litigation phase. Considering that a complaint by the EU against Turkey would be rare (if not the first) in the enforcement history of the WTO era, the upcoming procedures are closely followed by the interested parties. Having its impact on the ever-important pharmaceutical industry, the outcome of the dispute may require Turkey to undertake some fundamental revisions in its localization measures to comply with its international obligations. Against this backdrop, this article reviews the circumstances surrounding the EU's complaint along with the sensitive nerve-endings in the Turkish pharmaceutical system, which are brought under the review of the WTO dispute settlement regime.

Structure of Turkish pharmaceutical market

The primary legislation regulating human medicinal products is the Law No. 1262, which is implemented via the Regulation on Classification. The scope of this legislation covers natural or synthetic origin active substance or combination of substances administered to human beings for the purposes of treating or preventing a disease, making a diagnosis, correcting, regulating or modifying a physiological function. The main players of the Turkish medicinal markets are the producers and importers that supply the needs of the market along with the pharmaceutical warehouses and pharmacy stores that conduct the wholesale and retail sale of medicinal products, respectively. In the administrative front, the Agency mainly regulates the licensing affairs and the Social Securities Institution ("SSI") maintains the reimbursement functions, while the Ministry of Health holds general governance and supervision responsibilities.

There are separate licensing requirements for the undertakings operating in the production and supply of medicinal products. Such requirements are administrated by the Licensing Regulation, according to which human medicinal products cannot be released to the market before the required licenses are obtained. The administrative organ authorized for examining applications and issuing licenses regarding production, importation and sale of human medicinal products is the Agency. Licenses are valid until they are suspended or cancelled. In case the license for a certain human medicinal product is suspended or cancelled, production or importation of the product in question shall cease. The list of license cancellations is published by the Agency on an annual basis. At times of suspension or cancellation, it falls within the responsibilities of the Ministry of Health to decide on products, which are already placed on the market. Another function of the Ministry of Health is reviewing applications by license holders to assign their licenses to other real persons or legal entities, which is allowed in the Licensing Regulation.

With respect to the distribution activities, there is a separate licensing requirement. By virtue of the Regulation on Pharmaceutical Warehouses, wholesale of human medicinal products is conducted by licensed pharmaceutical warehouses. The same legislation also prohibits the distribution of unlicensed, imitated or defected products. In case of a failure to comply with this prohibition, the said products shall be withdrawn from the market in accordance with the Withdrawal Regulation.

In the payments and reimbursement front, a reference pricing system is followed in Turkey. Based on this system, the pricing of medicinal products are determined by the acceptance of the lowest ex-factory price to the warehouses in certain reference countries such as France, Italy, Spain, Portugal and Greece. Accordingly, the payments for such products are made in accordance with the reimbursement system for pharmaceuticals which stipulates a maximum of 10% above the lowest priced pharmaceuticals in the generic groups. Discounts may separately be applied by medicinal companies and pharmacy stores in public pharmaceutical purchases.

Accordingly, alternative procurement processes are regulated under the procurement processes foreseen in the SSI Regulation Concerning the General Health Insurance Alternative Reimbursement ("Regulation"). Based on this legislation, the procurement process is initiated by an application to be made to the SSI. The application might be made by companies or via administrative bodies. The applications are then examined by the relevant General Directorates within the SSI in accordance with the Regulation. These General Directorates make the initial technical and economic evaluations concerning the application, prepare draft reimbursement models and contracts to be submitted to the relevant divisions. In practice, the General Directorates may also include the relevant companies in the process by inviting their representatives to meetings. Subsequently, the relevant division would determine the final reimbursement models, the draft contracts and the price to be paid for the relevant health services, which would incentivize domestic production and increase exports. After such determination, the companies that satisfy the preliminary qualifications are singled out and invited to submit their bids. In the selection process, the relevant division is required by the Regulation to not only take into consideration the price but also other parameters such as quality, efficiency and technical superiority. Once process is consummated, the contract is signed by the representative of the company and the president of the SSI. The Regulation states that the relevant General Directorates would oversee implementation of the contract.

Turkish pharmaceutical market in numbers

Based on the data provided by the Pharmaceutical Manufacturers Association of Turkey, the market size of pharmaceuticals in Turkey has reached TL 33 billion (approximately USD 5.5 billion) for the last 12 months as of March 2019, while unit sales reached 2,3 billion units.

With respect to the product breakdown, oncology products has the largest share by value, which amounts to 12,8% of the total market. In terms of volume, antibiotic products and anti-rheumatism products represents the largest share in the total market, which amounts to 11.1%. When we focus on exports, pharmaceutical exportation in Turkey has reportedly reached USD 1173 million in the last 12 months as of March 2019. In a statement last year, the Minister of Health provided that local production amounts to 80% (in terms of units) of the total pharmaceuticals consumed in Turkey. However, the Minister adds that local production only amounts to 50% in terms of value. 1

Below are some key indicators of the market which provides a general overview as well as the breakdown between original-generic products and imported-local products extracted from the records of the Pharmaceutical Manufacturers Association of Turkey2:

Turkey's measures subject to the EU complaint

The measures subject to the EU's complaint to the WTO are mainly regulated within the framework of an Industry Cooperation Program in Health Services ("HICP"). The Communique on Applying Industry Cooperation Program in Health Service Areas ("Communique"), which is the to go legislation for the governance of the measures under scrutiny by the EU aims to incentivize domestic production of certain goods and services in the health sector that are being imported. The Communique provides a set of rules and principles where undertakings operating in the Turkish market for pharmaceutical products are imposed with certain responsibilities to cooperate with the relevant administrative bodies and to increase the domestic production. Accordingly, the overall cooperation mechanism entails a number of commitments imposed on relevant the undertakings, which are brought under the review of the WTO. To that end, there are four categories of commitments (A, B, C and D), which are explained below.

Category A (Local Support Contribution) - The contractor undertakes to produce high tech goods or its relevant parts by using existing production facilities and local industry abilities in Turkey (detailed information may be found on Annex – 1 of the Regulation). Category A commitments can be fulfilled through a partnership or a subcontractor. The Contractor may directly contribute to the joint production within the scope of Health ICP by using existing facilities and abilities of the producer. The Contractor may also use a domestic subcontractor regarding the production of aforementioned goods or services.

Category B (Investment) - The contractor undertakes to produce high tech goods or its relevant parts by a new production facility to be established (detailed information may be found on Annex – 2 of the Regulation). Category B refers to investments to be made by the Contractor. Commitments required in this category can be fulfilled through establishing a new production facility or by purchasing an existing facility. The Contractor may build a new facility for the production of the aforementioned goods and services within the scope of Health ICP. The Contractor may also purchase an existing facility and carry production activities.

Category C (Technological Cooperation) - The contractor undertakes to bring technological capabilities in the local industry. These obligations shall be fulfilled in guidance with activities referred to in Annex – 3 (detailed information may be found on Annex - 3 of the Regulation).

Category D (Export) - The Contractor undertakes to execute export activities in Turkey. These obligations shall be fulfilled in guidance with activities referred to in Annex 4 (detailed information may be found on Annex – 4 of the Regulation).

It should be noted that commitments within the context of Category C or Category D shall only be given together with Category A and/or Category B commitments. Against this backdrop, Hence, it will be prudent to break down the enforcement trends of the foregoing localization measures and have a grasp on the main points of objections by the EU.

Measures under review

In light of the foregoing, the EU's consultation request focus on certain measures adopted by Turkey as part of its centralized efforts to localize the production of pharmaceutical products in consumption. Overall, the EU argues that the implementation of the measures within the framework explained above rise discriminatory measures concerning trade-related investments. Accordingly, in essence, the EU's objections are concentrated on the following four Turkish measures.

Localization of production - With respect to the claims over the localization requirement, which is the main issue at hand, the EU argues that Turkey adopted comprehensive policies to localize the production of pharmaceutical products' consumed in Turkey. The EU argues that Turkey requires foreign producers to commit to localise their production in Turkey. In case of a failure to localize, the Turkish authorities are alleged to exclude the relevant enterprises from the social security reimbursement system. In the Turkish pharmaceutical landscape, the social security reimbursement scheme includes the majority of products in consumption. Therefore, the exclusion of the pharmaceutical companies who have failed to localize their productions from the fundamental reimbursement channel rises an anti-competitive barrier to foreign producers when compared to the domestic producers in Turkey. In other words, the EU claims that the reimbursement scheme of social security system constitutes a subsidy and the requirement to use domestic goods over imported goods in the localization requirements amounts to a prohibited subsidy. In addition, the EU also argues that measures are applied in a non-transparent manner and may differ from producer to producer.

Technology transfer requirement - As part of the localization requirement, the EU also claims that Turkey requires foreign producers to transfer the details of their technologies and use them through a producer established in Turkey. This allegation indicates that such technology transfer requirement include the patent rights. Accordingly, the EU argues that Turkey does not provide the same protection to EU derived intellectual rights when compared to the domestically derived intellectual property rights and the use of foreign patent rights subsequently face a discrimination. Furthermore, the EU stipulates in its consultation request that the restriction on the use of patent rights (such as sub-licensing) lead to the disclosure of confidential information pertaining to the foreign producers.

Import ban on localized products - The EU alleges that once the production of a given pharmaceutical product has been localised in Turkey, the import of that pharmaceutical product becomes prohibited. In other words, the claims stipulate that Turkey not only pressure the foreign producers to localize their production but also restricts import to solidify the now-localized production. 

Prioritization measure - The EU argues that in certain cases, where the imported products are not excluded from the reimbursement scheme, the Turkish authorities prioritize the applications of the domestic products to be included into the system over the imported products. Under this discrimination claim, the EU further argues that that the operations surrounding the system are not handled in a transparent manner. The application of measures are not uniform, impartial or reasonable,

Conclusion

The request for consultation initiates a formal dispute procedure between the parties before the WTO. If the parties cannot reach a mutually satisfactory solution at the end of the 60 days consultation, the EU may request the establishment of a panel, which will subsequently resolve the dispute. In a similar process dated 8 March 2017, Turkey requested a consultation with the United States ("US") for the countervailing measures applied to pipes and tubes. Upon failure of this consultation, Turkey requested the establishment of a panel, which has subsequently ruled that the relevant applications of the US were in violation of its obligations under the SCM.

The measures listed in the consultation request concern the production, import and marketing pharmaceutical products in Turkey. Therefore, every enterprise operating in the pharmaceutical sector may be effected by the outcome of the dispute at hand. As such, if the consultation leads to a litigation and the WTO adjudicating bodies rule in favor of the EU's arguments, Turkey will have to bring the relevant measures into conformity with its international obligations. In such a case, all the companies that operate or invest in the Turkish pharmaceutical sector will have to adopt their business plans, productions and supply chains in accordance with the new landscape.

Footnotes

1. https://www.turkiyegazetesi.com.tr/saglik/553740.aspx

2. http://www.ieis.org.tr/ieis/en/indicators/33/turkish-pharmaceutical-market

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions